Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapy product candidates for cancer, with its lead program ELI-002 7P aimed at mKRAS-driven tumors. The company does not yet have approved products or product revenue and is still centered on research, clinical development, and intellectual property protection.

2.38

2.38

— Elicio Therapeutics, Inc.
%
Clinical-stage oncology immunotherapy0% Lead and pipeline therapeutic candidates designed to treat cancer through immune-based mechanisms.
Preclinical drug discovery0% Early-stage programs and discovery work intended to generate future clinical candidates.
Platform technology licensing and development0% AMP platform and related intellectual property used to support internal development and potential partnering.
Collaboration and licensing arrangements0% Potential non-product revenue sources such as partnerships, licenses, or similar strategic deals.
Research and development services0% Internal and outsourced R&D activities supporting clinical and preclinical advancement.

Elicio does not currently sell approved products, so its near-term counterparties are primarily clinical investigators,...

  • Clinical development partnersprimary

    Investigators, CROs, and CMOs that execute trials, manufacture materials, and support regulatory development.

  • Strategic licensing partnersprimary

    Biopharma companies that may license or collaborate on the AMP platform or pipeline assets.

  • Future oncology providerssecondary

    Hospitals and oncology physicians that would prescribe the therapy if approved and clinically adopted.

  • Future payorssecondary

    Government and private payors that would determine coverage and reimbursement after approval.

Elicio is headquartered in Boston, Massachusetts, and operates as a U.S.-based clinical-stage biotech company...

  • •Headquartered in Boston, Massachusetts, United States
  • •Australian subsidiary supports research-credit eligible studies
  • •Clinical and discovery work may use foreign vendors and services
  • •No approved products, so no disclosed revenue geography yet

Elicio’s strategy is to advance ELI-002 7P into late-stage clinical trials, move preclinical programs into the clinic,...

01
Advance ELI-002 7P through late-stage developmentshort-term

The lead asset is the main value driver and the clearest path to clinical and regulatory validation.

02
Broaden the pipeline from preclinical to clinicalmedium-term

A deeper pipeline reduces single-asset dependence and improves long-term partnering optionality.

03
Protect intellectual property and platform valuelong-term

Patent coverage is central to differentiation, partnering leverage, and eventual commercialization.

Elicio faces the classic risks of a clinical-stage biotech: it has no approved products, recurring losses, and a need...

critical

Financing and going concern risk

The company has recurring operating losses and will need additional capital to fund development beyond its current runway.

Scope
Research and development, general and administrative spending, and clinical trial continuity
Materiality
high
high

Clinical and regulatory failure

Pipeline value depends on successful trial outcomes and FDA/foreign regulatory approvals, which are inherently uncertain.

Scope
ELI-002 7P and preclinical oncology programs
Materiality
high
high

Intellectual property protection

The company’s competitive position relies on patents for the AMP platform and specific cancer programs.

Scope
AMP platform, mKRAS, BRAF, and TP53 programs
Materiality
high
medium

Third-party manufacturing and vendor dependence

Clinical materials and services are outsourced, so vendor noncompliance or disruption can delay development.

Scope
CMOs, CROs, and foreign or foreign-owned suppliers
Materiality
medium
medium

Reimbursement and commercialization uncertainty

Even if approved, payor coverage and pricing pressure may limit adoption and economics.

Scope
Future oncology commercialization in the U.S. and abroad
Materiality
medium
Accrued research and development costs
Can shift operating expenses between quarters and affect comparability
Going concern assessment
Important for liquidity analysis and financing assumptions
Equity-based compensation
Affects reported operating loss and share-based dilution analysis
Collaboration and license accounting
Could materially affect revenue recognition timing if deals are signed

Xilio Therapeutics, Inc.

XLO · Pharmaceutical Preparations

Eledon Pharmaceuticals, Inc.

ELDN · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Immuneering Corp

IMRX · Pharmaceutical Preparations

Lexeo Therapeutics, Inc.

LXEO · Biological Products, (No Diagnostic Substances)

MAIA Biotechnology, Inc.

MAIA · Pharmaceutical Preparations

: 28/04/2026